Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification

Movement Disorders

Volumn 7, Issue 2, 1992, Pages 117-124

  Luquin, M R ^a   Scipioni, O ^b   Vaamonde, J ^a   Gershanik, O ^b   Obeso, José A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL FRANCÉS   (Argentina)

Author keywords

L dopa induced dyskinesias; Parkinson's disease

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; LISURIDE; SULPIRIDE;

ADULT; AGED; ARTICLE; CHOREA; DYSTONIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYOCLONUS; ON OFF PHENOMENON; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; APOMORPHINE; CHLORPROMAZINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; ELECTROMYOGRAPHY; FEMALE; HUMAN; LEVODOPA; LISURIDE; MALE; MIDDLE AGE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE; SULPIRIDE;

EID: 0026551551     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.870070204     Document Type: Article

References (29)

1. Hyperkinetic reactions with L‐dopa
2. L‐dopa therapy in Parkinson's disease: a critical review of nine years' experience
3. Levodopa‐induced dyskinesias: review, observations and speculation
4. Motor complications associated with chronic levodopa‐therapy in Parkinson's disease
5. Forms of dystonia in patients with Parkinson's disease
6. The pharmacology of foot dystonia in parkinsonism
7. Levodopa consumption reduces dopaminergic receptor responsivness in Parkinson's disease
8. Dystonia in Parkinson's disease: clinical and pharmacological features
9. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease
10. Subcutaneous apomorphine in the treatment of Parkinson's disease
11. Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 33 patients
12. Levodopa‐induced dopamine receptor hypersensitivity
13. Motor fluctuations in Parkinson's disease. Central pathophysiological mechanisms. Part I
14. Delayed onset of responses to single doses of L‐dopa in Parkinsonian fluctuators on long‐term L‐dopa therapy
15. Levodopa and 3‐O‐methyldopa plasma levels in Parkinsonian patients with stable and fluctuating motor response
16. Motor response following repeated apomorphine administration is reduced in Parkinson's disease
17. Complex dystonia of Parkinson's disease. Clinical features and relation to plama levodopa profile
18. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
19. Chronic treatment with L‐dopa, but not bromocriptine induces dyskinesia in MPTP‐parkinsonian monkeys: correlation with (3H)‐spiperone binding
20. Pathogenesis of dyskinesias in Parkinson's disease
21. Differential effects of D‐1 and D‐2 agonists in MPTP‐treated primates: functional implications for Parkinson's disease
22. Drugs with selective D‐1 or D‐2 receptor activity exhibit similar antiparkinsonian potency in the MPTP‐treated monkey
23. Strital inhomogeneities and basal ganglia function
24. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist induced dyskinesia in Parkinson's disease: implications for future strategies in treatment
25. Experimental hemichorea/hemibalismus in the monkey
26. Chorea and myoclonus in the monkey induced by Gammaaminobutiric acid antagonist in the lentiform complex
27. The role of the subthalamic nucleus in experimental chorea
28. Young onset Parkinson's disease